Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sunil Agarwal

Interventional Cardiology Springfield, IL Medical Doctor

NPI 1710204334 CMS profile 1379314

800 N 1St St, Springfield, IL 62702

Open in the dashboard

General payments

$23,870

175 records reported · program years 2019–2025

Research payments

$1,625

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$584,769 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Sunil Agarwal of Springfield, IL is reported in the CMS Open Payments database as having received $23,870 across 175 general payments and $1,625 in research payments paid to them. Separately, studies naming them as principal investigator received $584,769 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,134 34
2025 Research $1,625 12
2024 General $15,493 79
2023 General $1,536 35
2022 General $422 15
2021 General $47 3
2020 General $145 5
2019 General $93 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sunil Agarwal
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Sunil Agarwal were reported at $6,134. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Sunil Agarwal Interventional Cardiology median Middle half National median
2019 $93 $1,097 $329–$3,048 $163
2020 $145 $473 $161–$1,480 $114
2021 $47 $677 $233–$1,827 $132
2022 $422 $978 $333–$2,724 $149
2023 $1,536 $1,136 $382–$2,986 $160
2024 $15,493 $1,181 $395–$3,326 $164
2025 $6,134 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $12,500 1 payment
  2. Boston Scientific Corporation $5,487 8 payments
  3. Medtronic, Inc. $2,203 20 payments
  4. Abbott Laboratories $1,074 14 payments
  5. Edwards Lifesciences Corporation $708 4 payments
  6. Novartis Pharmaceuticals Corporation $645 90 payments
  7. Abiomed $557 6 payments
  8. AstraZeneca Pharmaceuticals LP $144 5 payments
  9. Averitas Pharma Inc. $114 1 payment
  10. Janssen Pharmaceuticals, Inc $100 6 payments
  11. Other $338 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,030 3 payments
  2. Food and Beverage $3,869 164 payments
  3. Travel and Lodging $1,971 8 payments
Products named General payments · program years 2019–2025
  1. General - Therapies $5,155 3 payments
  2. COREVALVE EVOLUT R $1,858 13 payments
  3. PROCLAIM $754 4 payments
  4. LEQVIO $615 88 payments
  5. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $530 1 payment
  6. Impella $422 5 payments
  7. ENTRESTO $294 43 payments
  8. VANTA ADAPTIVESTIM $288 4 payments
  9. OCTRODE $204 4 payments
  10. Edwards SAPIEN 3 Transcatheter Heart Valve $139 2 payments
  11. Other $1,346 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $1,625 12 payments

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

15,425

Median for Interventional Cardiology: 2,236

Drug cost

$2,171,077

Median for Interventional Cardiology: $380,412

Branded share of claims

28.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,174 $1,154,267
Xarelto Rivaroxaban Brand 197 $230,167
Entresto Sacubitril/Valsartan Brand 203 $206,506
Jardiance Empagliflozin Brand 131 $125,330
Praluent Pen Alirocumab Brand 89 $117,459
Repatha Sureclick Evolocumab Brand 92 $108,330
Brilinta Ticagrelor Brand 37 $34,831
Farxiga Dapagliflozin Propanediol Brand 34 $34,058
Metoprolol Succinate Generic 1,952 $20,715
Diltiazem 12hr Er Diltiazem Hcl Brand 123 $10,969

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$368,323

Of which drugs: $55,498

Medicare patients

2,117

Average age 75

Services billed

12,192

1,102 women, 1,015 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 47%
Diabetes 37%
Atrial fibrillation 33%
Heart failure 31%
COPD 30%
Chronic kidney disease 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, octafluoropropane microspheres, per ml Q9956 Office 76 223 $7,236
Injection, regadenoson, 0.1 mg J2785 Office 54 210 $1,093
Injection, dobutamine hydrochloride, per 250 mg J1250 Office 54 54 $378
Injection, atropine sulfate, 0.01 mg J0461 Office 13 13 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $236
$236 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $89
$89 203 —
Repatha
  • Amgen Inc. $25
$25 92 —
NEXLETOL
  • Esperion Therapeutics, Inc. $16
$16 — —
BRILINTA
  • AstraZeneca Pharmaceuticals LP $15
$15 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record